

08 March 2024

## Drugs treatment for Inflammatory Diseases

**Q1 – How many patients were treated with the following drugs for the following diseases from the start of Oct 2023 to the end of Dec 2023?**

*Please use the latest available 3 months if October to December is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.*

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis	Ankylosing spondylitis (inc. axial spondylitis)	Rheumatoid arthritis
Adalimumab (Humira)	24	26	6	135	67	60
Adalimumab (Biosimilars)	172	270	100	241	140	144
Apremilast				22		
Bimekizumab	7					
Brodalumab	0					
Certolizumab Pegol	7			56	26	22
Deucravacitinib	<5					
Etanercept (Enbrel)	<5			25	15	30
Etanercept (Biosimilars)	9			110	0	85
Guselkumab	84			<5		
Infliximab (Remicade)	<5	20	20	14	9	<5
Infliximab (Biosimilars)	<5	250	250	12	10	<5
Ixekizumab	58			71	21	
Risankizumab	87	5		<5		
Secukinumab	39			153	50	
Tildrakizumab	6					
Ustekinumab	72	180	20	8		
Upadacitinib		5	20	14	10	22
Vedolizumab		125	150			
Filgotinib			10			<5
Golimumab			10	52	25	<5
Mirikizumab			0			
Ozanimod			1			
Tofacitinib			6	5	<5	<5
Abatacept						112
Baricitinib						19
Rituximab						21
Sarilumab						<5
Tocilizumab						62

**08 March 2024**

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.